Summit Creek Advisors LLC boosted its position in shares of Repligen Co. (NASDAQ:RGEN) by 0.3% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 84,537 shares of the biotechnology company’s stock after purchasing an additional 230 shares during the quarter. Summit Creek Advisors LLC’s holdings in Repligen were worth $7,266,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in RGEN. Huntington National Bank purchased a new stake in Repligen during the 1st quarter valued at about $25,000. Royce & Associates LP grew its position in Repligen by 40.6% during the 1st quarter. Royce & Associates LP now owns 502 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 145 shares during the last quarter. Mascoma Wealth Management LLC purchased a new stake in Repligen during the 1st quarter valued at about $41,000. Private Capital Group LLC grew its position in Repligen by 675.3% during the 1st quarter. Private Capital Group LLC now owns 721 shares of the biotechnology company’s stock valued at $43,000 after purchasing an additional 628 shares during the last quarter. Finally, South Dakota Investment Council purchased a new stake in Repligen during the 1st quarter valued at about $83,000. 85.55% of the stock is currently owned by institutional investors.

RGEN traded up $1.61 during midday trading on Friday, hitting $92.51. 897,973 shares of the company traded hands, compared to its average volume of 568,757. The company has a quick ratio of 1.84, a current ratio of 2.18 and a debt-to-equity ratio of 0.03. The firm has a market cap of $4.29 billion, a price-to-earnings ratio of 126.73, a PEG ratio of 5.42 and a beta of 1.10. The firm has a 50-day moving average of $83.24. Repligen Co. has a 52 week low of $45.00 and a 52 week high of $93.35.

Repligen (NASDAQ:RGEN) last posted its earnings results on Thursday, May 9th. The biotechnology company reported $0.28 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.26 by $0.02. The business had revenue of $60.63 million for the quarter, compared to analysts’ expectations of $55.09 million. Repligen had a net margin of 10.11% and a return on equity of 6.35%. The business’s revenue for the quarter was up 35.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.17 EPS. On average, analysts expect that Repligen Co. will post 0.96 EPS for the current year.

Several analysts recently commented on the stock. Zacks Investment Research downgraded shares of Hallmark Financial Services from a “buy” rating to a “hold” rating in a research report on Thursday, July 18th. ValuEngine raised shares of United Overseas Bank from a “sell” rating to a “hold” rating in a research report on Monday, June 17th. HC Wainwright increased their price objective on shares of Cara Therapeutics from $28.00 to $31.00 and gave the company an “average” rating in a research report on Monday, July 22nd. Finally, BidaskClub downgraded shares of Woodward, Inc.Common Stock from a “strong-buy” rating to a “buy” rating in a research report on Saturday. Five research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $94.00.

In other Repligen news, Director Glenn L. Md Cooper sold 5,000 shares of the company’s stock in a transaction dated Thursday, May 23rd. The shares were sold at an average price of $66.94, for a total transaction of $334,700.00. Following the transaction, the director now owns 35,975 shares in the company, valued at approximately $2,408,166.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Karen A. Dawes sold 1,295 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $77.35, for a total transaction of $100,168.25. Following the transaction, the director now owns 118,329 shares in the company, valued at approximately $9,152,748.15. The disclosure for this sale can be found here. 1.70% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops, manufactures, and sells products used to enhance the interconnected phases of the biological drug manufacturing process in North America, Europe, APAC, and internationally. It offers Protein A ligands to life sciences companies, which are the binding components of Protein A affinity resins; and growth factor products used to supplement cell culture media.

Read More: 12b-1 Fees

Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Co. (NASDAQ:RGEN).

Institutional Ownership by Quarter for Repligen (NASDAQ:RGEN)

Receive News & Ratings for Repligen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen and related companies with MarketBeat.com's FREE daily email newsletter.